A Phase 3, Randomized, Multicenter, Double Blind, Placebo and Active Comparator-Controlled Study with a Randomized Withdrawal and Retreatment Period to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 in subjects with moderate to severe